trending Market Intelligence /marketintelligence/en/news-insights/trending/XsXwD1g71DALuSiUT_N5Tg2 content esgSubNav
In This List

Report: Vivo Capital looks to exit Surgical Specialties

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

Banking Essentials Newsletter: July Edition - Part 2

Blog

Anticipate the Unknown Go Beyond Fundamentals to Uncover Early Signs of Private Company Credit Deterioration


Report: Vivo Capital looks to exit Surgical Specialties

Vivo Capital LLC is weighing a sale for Surgical Specialties Corp. and hired an adviser to gauge buyer interest, Bloomberg News reported, citing people with knowledge of the matter.

The medical-device maker could be worth more than $500 million.

Vivo Capital and ZQ Capital Ltd. co-led an investor group to acquire the Canadian company, then known as Angiotech Pharmaceuticals Inc., in 2017, Bloomberg said.

Representatives for Vivo Capital and Surgical Specialties did not immediately answer requests for comment, according to Bloomberg.